Jove
Visualize
Contact Us

Related Experiment Videos

Standardization of mPEG-modified allergens.

S Dreborg

    Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt Fur Sera Und Impfstoffe) Zu Frankfurt A.M
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Epinephrine auto-injectors: information, education, training and acceptance.

    Allergologia et immunopathologia·2019
    Same author

    Current practice of allergy diagnosis and the potential impact of regulation in Europe.

    Allergy·2017
    Same author

    Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients.

    International archives of allergy and immunology·2012
    Same author

    Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.

    Allergy·2007
    Same author

    Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.

    Allergy·2006
    Same author

    Variability of airborne cat allergen, Fel d1, in a public place.

    Indoor air·2003
    Same journal

    Quality and clinical efficacy of allergen mixtures.

    Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
    Same journal

    A bright future for sublingual immunotherapy--contra.

    Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
    Same journal

    A bright future for sublingual immunotherapy?--pro.

    Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
    Same journal

    Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.

    Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
    Same journal

    Prospects for CpG based immunotherapy in asthma and allergy.

    Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
    Same journal

    Understanding the immunological basis of asthma; immunotherapy and regulatory T cells.

    Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Standardizing modified polyethylene glycol- (mPEG-) allergens requires consistent production and rigorous testing for allergenicity and protein content. This approach serves as a model for future modified allergen standardization, urging regulatory bodies to establish clear registration criteria.

    Area of Science:

    • Biochemistry
    • Immunology
    • Pharmaceutical Science

    Background:

    • The development of modified allergens, such as those using polyethylene glycol (PEG), offers potential therapeutic benefits but necessitates robust standardization methods.
    • Ensuring batch-to-batch consistency and predictable efficacy in modified allergen products is crucial for patient safety and regulatory approval.

    Purpose of the Study:

    • To outline a comprehensive approach for the standardization of mPEG-modified allergens.
    • To propose a model for the standardization of all modified allergens.
    • To advocate for stricter regulatory criteria for the registration and continued approval of modified allergen products.

    Main Methods:

    • Standardizing the native allergens based on established principles.
    • Employing reproducible methods for the production of mPEG-modified allergens.

    Related Experiment Videos

  • Implementing quality control measures including estimation of allergenicity, protein content, and the degree of PEGylation.

    • Main Results:

    • A framework for mPEG-modified allergen standardization is presented, focusing on reproducible production and rigorous quality control.
    • The proposed methods allow for the estimation of allergenicity, protein content, and the degree of modification, ensuring batch consistency.
    • The standardization of mPEG-modified allergens is proposed as a model for other modified allergens.

    Conclusions:

    • Standardization of mPEG-modified allergens can be achieved through consistent production and thorough quality control of allergenicity and protein content.
    • This standardization process serves as a valuable model for other modified allergens.
    • There is a need for European regulatory authorities to implement stringent criteria for the registration and ongoing evaluation of modified allergen products based on safety and efficacy data.